Detalles de la búsqueda
1.
Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
Br J Clin Pharmacol
; 90(1): 274-285, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37621050
2.
Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants.
Br J Clin Pharmacol
; 89(7): 2236-2245, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36822839
3.
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.
Clin Infect Dis
; 75(5): 786-794, 2022 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34996113
4.
GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile.
Antimicrob Agents Chemother
; 66(1): e0187621, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34780263
5.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis
; 71(8): 1920-1929, 2020 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31905383
6.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet
; 393(10167): 143-155, 2019 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30420123
7.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Lancet
; 391(10123): 839-849, 2018 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29310899
8.
A phase I, first-in-human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937.
Pharmacol Res Perspect
; 11(3): e01093, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269076
9.
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
AIDS
; 36(1): 39-48, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34534138
10.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr
; 85(3): 325-330, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32675772
11.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr
; 83(3): 310-318, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31834000
12.
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
J Acquir Immune Defic Syndr
; 84(1): 60-65, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31977595
13.
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Lancet HIV
; 6(9): e576-e587, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31307948
14.
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Lancet Infect Dis
; 19(3): 253-264, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30732940
15.
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
AIDS
; 32(4): 477-485, 2018 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29239893
16.
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Antivir Ther
; 18(7): 905-13, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23899468
Resultados
1 -
16
de 16
1
Próxima >
>>